Vanda Pharmaceuticals (VNDA) Receivables (2010 - 2026)

Vanda Pharmaceuticals' Receivables history runs 17 years deep, the most recent figure standing at $56.9 million for Q1 2026.

• In Q1 2026, Receivables rose 27.52% year-over-year to $56.9 million; the TTM figure through Mar 2026 stood at $56.9 million (up 27.52% YoY), while the FY2025 annual figure was $54.6 million, up 15.87% from the prior year.
• Receivables came in at $56.9 million for Q1 2026 at Vanda Pharmaceuticals, up from $54.6 million in the prior quarter.
• In the past five years, Receivables ranged from a high of $56.9 million in Q1 2026 to a low of $24.5 million in Q1 2023.
• A 5-year average of $39.0 million and a median of $36.7 million in 2024 frame the typical range for Receivables.
• Across the five-year window, Receivables declined 29.27% in 2022 and jumped 49.77% in 2024, its largest moves.
• Vanda Pharmaceuticals' Receivables stood at $33.5 million in 2022, then gained by 1.92% to $34.2 million in 2023, then jumped by 37.9% to $47.1 million in 2024, then rose by 15.87% to $54.6 million in 2025, then increased by 4.22% to $56.9 million in 2026.
• According to Business Quant data, Receivables over the past three periods registered $56.9 million, $54.6 million, and $50.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison